{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:57:53Z","timestamp":1761764273390},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"944","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,6,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>For patients with urological cancers, immunotherapy is currently a treatment option for metastatic renal cell carcinoma, and those with \u201chigh risk\u201d superficial bladder cancers. In this review, our current understanding of tumour immune escape is discussed. The principles and role of current immunotherapies for these tumours are described, and new areas of immunotherapeutic promise are highlighted.<\/jats:p>","DOI":"10.1136\/pgmj.2003.013508","type":"journal-article","created":{"date-parts":[[2004,6,10]],"date-time":"2004-06-10T20:23:34Z","timestamp":1086899014000},"page":"320-327","source":"Crossref","is-referenced-by-count":4,"title":["Evolving immunotherapeutic strategies in bladder and renal cancer"],"prefix":"10.1093","volume":"80","author":[{"given":"T R L","family":"Griffiths","sequence":"first","affiliation":[{"name":"Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester General Hospital , Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J K","family":"Mellon","sequence":"additional","affiliation":[{"name":"Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester General Hospital , Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,6,10]]},"reference":[{"key":"2023050810274782800_R1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S0022-5347(17)57611-9","article-title":"Renal cell carcinoma: natural history and results of treatment.","volume":"119","author":"Patel","year":"1978","journal-title":"J Urol"},{"key":"2023050810274782800_R2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon-alfa alone in metastatic renal-cell carcinoma: a randomised trial.","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"2023050810274782800_R3","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"2023050810274782800_R4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","article-title":"A prospective European Organisation for Research and Treatment of Cancer Genitourinary Group randomised trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in a single stage T1 papillary carcinoma of bladder.","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J Urol"},{"key":"2023050810274782800_R5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"2023050810274782800_R6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0022-5347(17)59915-2","article-title":"The plight of the patient with carcinoma in situ of the bladder.","volume":"111","author":"Utz","year":"1970","journal-title":"J Urol"},{"key":"2023050810274782800_R7","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomised clinical trials.","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"2023050810274782800_R8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/icb.1975.3","article-title":"A new analysis of allogeneic interactions.","volume":"53","author":"Lafferty","year":"1975","journal-title":"Aust J Exp Biol Med Sci"},{"key":"2023050810274782800_R9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self.","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"2023050810274782800_R10","first-page":"3","article-title":"Immunological surveillance in neoplasia.","volume":"7","author":"Burnet","year":"1971","journal-title":"Transplant Rev"},{"key":"2023050810274782800_R11","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(99)04435-9","article-title":"Selection of metastatic tumour phenotypes by host immune systems.","volume":"354","author":"Semour","year":"1999","journal-title":"Lancet"},{"key":"2023050810274782800_R12","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/1097-0142(19911215)68:12<2591::AID-CNCR2820681212>3.0.CO;2-L","article-title":"Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival.","volume":"68","author":"Levin","year":"1991","journal-title":"Cancer"},{"key":"2023050810274782800_R13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/bjc.1995.346","article-title":"Frequency of downregulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression.","volume":"72","author":"Keating","year":"1995","journal-title":"Br J Cancer"},{"key":"2023050810274782800_R14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2249.1999.00857.x","article-title":"Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD+ T cell activation in vitro.","volume":"116","author":"Pettit","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"2023050810274782800_R15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/1097-0045(20001001)45:2<167::AID-PROS11>3.0.CO;2-J","article-title":"TGF-beta-based immunotherapy for cancer: breaching the tumour firewall.","volume":"45","author":"Shah","year":"2000","journal-title":"Prostate"},{"key":"2023050810274782800_R16","first-page":"42","article-title":"Chemotherapy for advanced renal-cell carcinoma: 1983 to 1993.","volume":"22","author":"Yagoda","year":"1995","journal-title":"Semin Oncol"},{"key":"2023050810274782800_R17","first-page":"298","article-title":"Expression of a multi-drug resistance gene in human tumours (abstract).","volume":"29","author":"Goldstein","year":"1988","journal-title":"Proc Am Assoc Cancer Res"},{"key":"2023050810274782800_R18","first-page":"801","article-title":"Immunotherapy in renal cell carcinoma.","volume":"13","author":"Bukowski","year":"1999","journal-title":"Oncology"},{"key":"2023050810274782800_R19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(98)03544-2","article-title":"Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial.","volume":"353","author":"Medical Research Council Renal Cancer Collaborators","year":"1999","journal-title":"Lancet"},{"issue":"suppl","key":"2023050810274782800_R20","first-page":"S55","article-title":"Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.","volume":"6","author":"Fisher","year":"2000","journal-title":"Cancer J Sci Am"},{"issue":"suppl 1","key":"2023050810274782800_R21","first-page":"S85","article-title":"Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.","volume":"3","author":"Gold","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"2023050810274782800_R22","first-page":"S79","article-title":"An ongoing prospective randomised comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.","volume":"3","author":"Yang","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"2023050810274782800_R23","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199804303381804","article-title":"Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.","volume":"338","author":"Gleave","year":"1998","journal-title":"N Engl J Med"},{"key":"2023050810274782800_R24","first-page":"1176","article-title":"Interactive effects of alpha-interferon A\/D and interleukin 2 on murine lymphokine activayed killer activity: analysis at the effector and precursor level.","volume":"50","author":"Chikkala","year":"1990","journal-title":"Cancer Res"},{"key":"2023050810274782800_R25","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Group Francais d\u2019Immunotheapie.","volume":"338","author":"Negrier","year":"1998","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"2023050810274782800_R26","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/0959-8049(93)90617-O","article-title":"Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell carcinoma.","volume":"29A","author":"Atzpodien","year":"1993","journal-title":"Eur J Cancer"},{"key":"2023050810274782800_R27","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1054\/bjoc.2001.2076","article-title":"IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomised clinical trial.","volume":"85","author":"Atzpodien","year":"2001","journal-title":"Br J Cancer"},{"key":"2023050810274782800_R28","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2000.18.24.4009","article-title":"Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d\u2019Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer.","volume":"18","author":"Negrier","year":"2000","journal-title":"J Clin Oncol"},{"key":"2023050810274782800_R29","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.1999.17.9.2859","article-title":"Prospective randomised trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.","volume":"17","author":"Pyrhonen","year":"1999","journal-title":"J Clin Oncol"},{"key":"2023050810274782800_R30","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1200\/JCO.2000.18.16.2972","article-title":"Phase III trial of alfa-2a with or without 13-cis retinoic acid for patients with advanced renal cell carcinoma.","volume":"18","author":"Motzer","year":"2000","journal-title":"J Clin Oncol"},{"key":"2023050810274782800_R31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/sj.bjc.6600152","article-title":"Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma.","volume":"86","author":"Sasamura","year":"2002","journal-title":"Br J Cancer"},{"key":"2023050810274782800_R32","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","article-title":"Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.","volume":"82","author":"Eisen","year":"2000","journal-title":"Br J Cancer"},{"key":"2023050810274782800_R33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0022-5347(17)57082-2","article-title":"The natural history of metastatic renal cell carcinoma: a computer analysis.","volume":"120","author":"Dekernion","year":"1978","journal-title":"J Urol"},{"key":"2023050810274782800_R34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma.","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"2023050810274782800_R35","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJM200112063452317","article-title":"Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.","volume":"345","author":"Pantuck","year":"2001","journal-title":"N Engl J Med"},{"key":"2023050810274782800_R36","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jnci\/85.8.622","article-title":"Prospective randomised trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.","volume":"85","author":"Rosenberg","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2023050810274782800_R37","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.1999.17.8.2521","article-title":"Multicenter, randomised, phase III trial of CD8(+) tumour-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.","volume":"17","author":"Figlin","year":"1999","journal-title":"J Clin Oncol"},{"key":"2023050810274782800_R38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0959-8049(97)00002-6","article-title":"Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients.","volume":"33","author":"Santarosa","year":"1997","journal-title":"Eur J Cancer"},{"key":"2023050810274782800_R39","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","article-title":"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.","volume":"343","author":"Childs","year":"2000","journal-title":"N Engl J Med"},{"key":"2023050810274782800_R40","first-page":"97","article-title":"Cancer and tuberculosis.","volume":"9","author":"Pearl","year":"1929","journal-title":"Am J Hyg"},{"key":"2023050810274782800_R41","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/1097-0142(197410)34:8+<1532::AID-CNCR2820340827>3.0.CO;2-H","article-title":"Immunotherapy of guinea pig cancer with BCG.","volume":"34","author":"Zbar","year":"1974","journal-title":"Cancer"},{"key":"2023050810274782800_R42","first-page":"423","article-title":"The effects of BCG on the dog bladder.","volume":"12","author":"Bloomberg","year":"1975","journal-title":"Invest Urol"},{"key":"2023050810274782800_R43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumours.","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"2023050810274782800_R44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(01)66427-9","article-title":"Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomised study in patients with recurrent superficial bladder tumours.","volume":"155","author":"Luftenegger","year":"1996","journal-title":"J Urol"},{"key":"2023050810274782800_R45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-5347(01)65185-1","article-title":"Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette Guerin during intravesical treatment of superficial bladder cancer.","volume":"157","author":"Zlotta","year":"1997","journal-title":"J Urol"},{"key":"2023050810274782800_R46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1006\/smim.1998.0143","article-title":"An innate sense of danger.","volume":"10","author":"Matzinger","year":"1998","journal-title":"Semin Immunol"},{"key":"2023050810274782800_R47","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0022-5347(05)65522-X","article-title":"T helper 1\/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.","volume":"166","author":"Saint","year":"2001","journal-title":"J Urol"},{"key":"2023050810274782800_R48","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","article-title":"A randomised study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa\u2013pT1 papillary carcinoma and carcinoma in situ of the bladder.","volume":"153","author":"Vegt","year":"1995","journal-title":"J Urol"},{"issue":"suppl 2","key":"2023050810274782800_R49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1442-2042.1995.tb00476.x","article-title":"Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness, and what are their limitations and uses?","volume":"2","author":"Lamm","year":"1995","journal-title":"Int J Urol"},{"key":"2023050810274782800_R50","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0022-5347(01)62377-2","article-title":"Results of a randomised phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.","volume":"160","author":"Witjes","year":"1998","journal-title":"J Urol"},{"key":"2023050810274782800_R51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/21681805.1991.12068885","article-title":"Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group.","volume":"138","author":"Bouffioux","year":"1991","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"2023050810274782800_R52","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomised Southwest Oncology study.","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"2023050810274782800_R53","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0022-5347(01)65396-5","article-title":"A combined analysis of European Organisation for Research and Treatment of Cancer, and Medical Research Council randomised clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group, and the Medical Research Council Working Party on Superficial Bladder Cancer.","volume":"156","author":"Pawinski","year":"1996","journal-title":"J Urol"},{"key":"2023050810274782800_R54","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"key":"2023050810274782800_R55","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomised prospective trial comparing a standard 81 mg dose of intravesical bacillus Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer.","volume":"89","author":"Martinez Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"2023050810274782800_R56","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumours.","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"2023050810274782800_R57","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","article-title":"Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organisation for Research and Treatment of Cancer Protocol 30911.","volume":"157","author":"Vegt","year":"1997","journal-title":"J Urol"},{"key":"2023050810274782800_R58","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0022-5347(05)65642-X","article-title":"Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder.","volume":"166","author":"Morales","year":"2001","journal-title":"J Urol"},{"key":"2023050810274782800_R59","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.","volume":"166","author":"O\u2019Donnell","year":"2001","journal-title":"J Urol"},{"key":"2023050810274782800_R60","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2249.2001.01428.x","article-title":"Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity.","volume":"123","author":"Luo","year":"2001","journal-title":"Clin Exp Immunol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/80\/944\/320\/50224635\/postgradmedj-80-320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/80\/944\/320\/50224635\/postgradmedj-80-320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T10:29:10Z","timestamp":1683541750000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/80\/944\/320\/7036194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":60,"journal-issue":{"issue":"944","published-online":{"date-parts":[[2004,6,10]]},"published-print":{"date-parts":[[2004,6,10]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2003.013508","relation":{},"ISSN":["1469-0756","0032-5473"],"issn-type":[{"value":"1469-0756","type":"electronic"},{"value":"0032-5473","type":"print"}],"subject":[],"published-other":{"date-parts":[[2004,6]]},"published":{"date-parts":[[2004,6]]}}}